약물동태학 서비스 시장 규모, 점유율, 동향 분석 보고서 : 의약품 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2023-2030년)
Pharmacokinetics Services Market Size, Share & Trends Analysis Report By Drug Type (Small Molecules), By Application (SMEs) By End-use (Biotechnology & Pharmaceutical Companies) By Region, And Segment Forecasts, 2023 - 2030
상품코드
:
1363133
리서치사
:
Grand View Research, Inc.
발행일
:
2023년 09월
페이지 정보
:
영문 110 Pages
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
약물동태학 서비스 시장 성장 및 동향 :
세계의 약물동태학 서비스(PK 서비스, Pharmacokinetics Services) 시장 규모는 2023년부터 2030년까지 CAGR 7.5%로 추이하며 성장 할 것으로 예상되며, 2030년까지 17억 6,240만 달러에 이를 전망입니다.
관찰되지 않은 효과 수준(NOEL), 인체 등가 용량(HED) 수준, 약동학/약력학(PK/PD) 동인 등 여러 파라미터를 결정하기 위한 약동학 및 독성학 연구의 채택이 증가함에 따라 시장 성장이 촉진될 것으로 예상됩니다.
잠재적 약물 후보의 약동학 프로필을 철저히 이해하는 것은 신약 개발 프로그램의 성공에 중요한 역할을 합니다. 이 외에도 규제 기관은 PK 연구 수행을 위한 정의된 지침을 수립함으로써 이 시장의 발전에 중요한 역할을 해왔습니다. 관련 EMEA, ICH, FDA, GCP 및 기타 규제 지침에 따라 PK 연구를 수행하는 CRO가 상당수 존재합니다.
신약 개발 프로세스에서 PK 서비스를 효과적으로 구현하는 것에 대한 관심이 높아지면서 이 분야에 대한 투자가 증가할 것으로 예상됩니다. 임상 및 전임상 약물 개발에서 약동학 적용과 관련된 다양한 패러다임에 대한 이해를 높이기 위해 전 세계적으로 여러 컨퍼런스 및 인증 과정이 진행되고 있습니다.
약물동태학 서비스 시장 보고서 하이라이트
- 의약품 유형별로는 저분자가 2022년의 수익 점유율 76.7%로 시장을 독점하고, 예측 기간 동안에도 서비스의 높은 보급률과 제네릭 의약품의 인기가 높아짐에 따라 리드를 유지할 것으로 예상됩니다.
- 고분자의 PK 분석은 임상 개발 단계에서 다수의 생물학적 제제와 바이오시밀러의 존재로 인해 예측 기간 동안 크게 성장할 것으로 예상됩니다.
- 미국에는 수많은 바이오의약품 및 의약품 제조업체가 존재하기 때문에 2022년에는 북미가 최대의 점유율을 차지하게 됩니다.
- 아시아 태평양은 예측 기간 중 가장 빠른 CAGR 9.2%로 확대될 것으로 예측됩니다. 이는 여러 나라에서 끊임없는 경제 성장으로 인해 세계 CRO로부터 큰 주목을 받고 사업 확대로 이어졌기 때문입니다.
- Pharmaceutical Product Development, LLC, Charles River Laboratories International, Inc., PAREXEL International Corporation, Eurofins Scientific, Inc. 등이 주요 서비스 제공 업체입니다.
- 이 CRO는 새로운 시장의 길을 개척하고 향후 시장 점유율을 높이기 위해 다양한 노력을 기울이고 있습니다.
목차
제1장 조사 방법 및 범위
제2장 주요 요약
제3장 약물동태학 서비스 시장의 변수, 동향, 범위
- 시장 계통 전망
- 보급 및 성장 전망 매핑
- 시장 역학
- 시장 성장 촉진 요인 분석
- 시장 성장 억제 요인 분석
- 약물동태학 서비스 시장 분석 도구
- 산업 분석-Porter's Five Forces 분석
- PESTEL 분석
제4장 약물동태학 서비스 시장 : 의약품 유형별 추정·동향 분석
- 약물동태학 서비스 시장, 중요 포인트
- 약물동태학 서비스 시장 : 동향 및 시장 점유율 분석(2022년, 2030년)
- 저분자
- 고분자(바이오의약품)
제5장 약물동태학 서비스 시장 : 용도별 추정·동향 분석
- 약물동태학 서비스 시장, 중요 포인트
- 약물동태학 서비스 시장 : 동향 및 시장 점유율 분석(2022년, 2030년)
- 중소기업
- 대기업
제6장 약물동태학 서비스 시장 : 최종 용도별 추정·동향 분석
- 약물동태학 서비스 시장, 중요 포인트
- 약물동태학 서비스 시장 : 동향 및 시장 점유율 분석(2022년, 2030년)
- 생명공학 및 제약회사
- 학술 및 정부의 연구기관
- 기타
제7장 약물동태학 서비스 시장 : 지역별 추정·동향 분석
- 지역별 전망
- 지역별 약물동태학 서비스 시장 : 중요 포인트
- 북미
- 시장 추정 및 예측(2018-2030년)
- 미국
- 캐나다
- 유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
- 아시아 태평양
- 남미
- 중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트
제8장 경쟁 구도
- 주요 시장 진출기업에 의한 최근 동향 및 영향 분석
- 시장 진출기업 분류
- Evotec AG
- Certara, LP
- Pacific BioLabs
- GVK Biosciences Private Limited
- Shanghai Medicilon Inc.
- Pharmaceutical Product Development, LLC
- Charles River Laboratories International, Inc.
- PAREXEL International Corporation
- Eurofins Scientific, Inc.
- Frontage Labs
- SGS SA
- LGC Limited
- Creative Bioarray
LYJ
영문 목차
Pharmacokinetics Services Market Growth & Trends:
The global pharmacokinetics services market size is expected to reach USD 1,762.4 million by 2030, registering a CAGR of 7.5% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Rising adoption of pharmacokinetic and toxicology studies for determination of several parameters such as no-observed-effect levels (NOEL), human equivalent doses (HED) levels, and pharmacokinetic/pharmacodynamic (PK/PD) drivers are expected to fuel market growth.
Thorough understanding of the pharmacokinetic profile of a potential drug candidate plays a major role in the success of a drug discovery program. In addition to this, regulatory bodies have played a major role in the progress of this market through establishing defined guidelines for conducting PK studies. There are a substantial number of CROs engaged in conducting PK studies in accordance with relevant EMEA, ICH, FDA, GCP, and other regulatory guidelines.
Growing concern for effective implementation of PK services in the drug development process is anticipated to drive investments in this sector. Several conferences and certification courses are being conducted across the world to increase the understanding of various paradigms associated with pharmacokinetics application in clinical and preclinical drug development.
Pharmacokinetics Services Market Report Highlights:
- Based on drug type, Small molecule dominated the market with a revenue share of 76.7% in 2022 and is expected to maintain its lead during the forecast period fueled by high service penetration and growing popularity of generics
- PK analysis for large molecules are expected to grow significantly during the forecast period, driven by presence of significant number of biologics and biosimilars in the clinical development phase
- Presence of a large number of biopharmaceutical and pharmaceutical manufacturing entities in U.S. has resulted in North America accounting for the largest share in 2022
- Asia Pacific is estimated to expand at the fastest CAGR of 9.2% over the forecast period thanks to constant economic growth in several countries, which has attracted significant attention from global CROs and resulted in business expansions
- Pharmaceutical Product Development, LLC; Charles River Laboratories International, Inc.; PAREXEL International Corporation; and Eurofins Scientific, Inc. are some of the key service providers
- These CROs are undertaking various initiatives in order to capitalize on new market avenues and enhance their share in the future market.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Drug Type
- 1.1.2. Application
- 1.1.3. End use
- 1.1.4. Regional scope
- 1.1.5. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.4.1. Data analysis models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Drug Type outlook
- 2.2.2. Application outlook
- 2.2.3. End use outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Pharmacokinetic Services Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Market Dynamics
- 3.3.1. Market driver analysis
- 3.3.2. Market restraint analysis
- 3.4. Pharmacokinetic Services Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's
- 3.4.1.1. Supplier power
- 3.4.1.2. Buyer power
- 3.4.1.3. Substitution threat
- 3.4.1.4. Threat of new entrant
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Technological landscape
- 3.4.2.3. Economic landscape
Chapter 4. Pharmacokinetic Services Market: Drug Type Estimates & Trend Analysis
- 4.1. Pharmacokinetic Services Market, Key Takeaways
- 4.2. Pharmacokinetic Services Market: Movement & Market Share Analysis, 2022 & 2030
- 4.3. Small Molecule
- 4.3.1. Small molecule market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4. Large Molecules (Biopharmaceuticals)
- 4.4.1. Large molecule (biopharmaceuticals) market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Pharmacokinetic Services Market: Application Estimates & Trend Analysis
- 5.1. Pharmacokinetic Services Market, Key Takeaways
- 5.2. Pharmacokinetic Services Market: Movement & Market Share Analysis, 2022 & 2030
- 5.3. Small and Medium Enterprise
- 5.3.1. Small and medium enterprise market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4. Large Enterprise
- 5.4.1. Large enterprise market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Pharmacokinetic Services Market: End Use Estimates & Trend Analysis
- 6.1. Pharmacokinetic Services Market, Key Takeaways
- 6.2. Pharmacokinetic Services Market: Movement & Market Share Analysis, 2022 & 2030
- 6.3. Biotechnology & Pharmaceutical Companies
- 6.3.1. Biotechnology & pharmaceutical companies market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.4. Academic & Government Research Institutes
- 6.4.1. Academic & government research institutes market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.5. Others
- 6.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Pharmacokinetic Services Market: Regional Estimates & Trend Analysis
- 7.1. Regional Outlook
- 7.2. Pharmacokinetic Services Market by Region: Key Takeaways
- 7.3. North America
- 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.3.2. U.S.
- 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.3.3. Canada
- 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4. Europe
- 7.4.1. UK
- 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.2. Germany
- 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.3. France
- 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.4. Italy
- 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.5. Spain
- 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.6. Denmark
- 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.7. Sweden
- 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.4.8. Norway
- 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5. Asia Pacific
- 7.5.1. Japan
- 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.2. China
- 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.3. India
- 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.4. Australia
- 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.5. Thailand
- 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.5.6. South Korea
- 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6. Latin America
- 7.6.1. Brazil
- 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6.2. Mexico
- 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.6.3. Argentina
- 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7. MEA
- 7.7.1. South Africa
- 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.2. Saudi Arabia
- 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.3. UAE
- 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 7.7.4. Kuwait
- 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Market Participant Categorization
- 8.2.1. Evotec AG
- 8.2.1.1. Company overview
- 8.2.1.2. Financial performance
- 8.2.1.3. Product benchmarking
- 8.2.1.4. Strategic initiatives
- 8.2.2. Certara, L.P.
- 8.2.2.1. Company overview
- 8.2.2.2. Financial performance
- 8.2.2.3. Product benchmarking
- 8.2.2.4. Strategic initiatives
- 8.2.3. Pacific BioLabs
- 8.2.3.1. Company overview
- 8.2.3.2. Financial performance
- 8.2.3.3. Product benchmarking
- 8.2.3.4. Strategic initiatives
- 8.2.4. GVK Biosciences Private Limited
- 8.2.4.1. Company overview
- 8.2.4.2. Financial performance
- 8.2.4.3. Product benchmarking
- 8.2.4.4. Strategic initiatives
- 8.2.5. Shanghai Medicilon Inc.
- 8.2.5.1. Company overview
- 8.2.5.2. Financial performance
- 8.2.5.3. Product benchmarking
- 8.2.5.4. Strategic initiatives
- 8.2.6. Pharmaceutical Product Development, LLC
- 8.2.6.1. Company overview
- 8.2.6.2. Financial performance
- 8.2.6.3. Product benchmarking
- 8.2.6.4. Strategic initiatives
- 8.2.7. Charles River Laboratories International, Inc.
- 8.2.7.1. Company overview
- 8.2.7.2. Financial performance
- 8.2.7.3. Product benchmarking
- 8.2.7.4. Strategic initiatives
- 8.2.8. PAREXEL International Corporation
- 8.2.8.1. Company overview
- 8.2.8.2. Financial performance
- 8.2.8.3. Product benchmarking
- 8.2.8.4. Strategic initiatives
- 8.2.9. Eurofins Scientific, Inc.
- 8.2.9.1. Company overview
- 8.2.9.2. Financial performance
- 8.2.9.3. Product benchmarking
- 8.2.9.4. Strategic initiatives
- 8.2.10. Frontage Labs
- 8.2.10.1. Company overview
- 8.2.10.2. Financial performance
- 8.2.10.3. Product benchmarking
- 8.2.10.4. Strategic initiatives
- 8.2.11. SGS SA
- 8.2.11.1. Company overview
- 8.2.11.2. Financial performance
- 8.2.11.3. Product benchmarking
- 8.2.11.4. Strategic initiatives
- 8.2.12. LGC Limited
- 8.2.12.1. Company overview
- 8.2.12.2. Financial performance
- 8.2.12.3. Product benchmarking
- 8.2.12.4. Strategic initiatives
- 8.2.13. Creative Bioarray
- 8.2.13.1. Company overview
- 8.2.13.2. Financial performance
- 8.2.13.3. Product benchmarking
- 8.2.13.4. Strategic initiatives
관련자료
